Toradol is the common brand name for ketorolac tromethamine, a prescription strength pain reliever that shows up often in emergency rooms, urgent care clinics, and surgical recovery rooms. It is also one of the medications an injured worker is most likely to receive right before a post accident drug test, which is why the question comes up so often. This article explains what Toradol actually is, how standard workplace drug test panels are built, why ketorolac is not a target of those panels, and what the medical review officer process does with any result that still needs a second look.
What Toradol actually is
Ketorolac tromethamine is a nonsteroidal anti inflammatory drug, the same broad family as ibuprofen and naproxen, but considerably more potent and intended only for short term use. According to the current prescribing information on DailyMed, the federal label repository maintained by the National Library of Medicine, ketorolac is approved for the short term management of moderately severe acute pain that requires analgesia at the opioid level, and combined duration of use across all routes generally should not exceed five days. The same label lists the drug's DEA schedule as none, meaning ketorolac is not a federally controlled substance the way an opioid painkiller is.
Clinically, ketorolac is used after orthopedic surgery, dental procedures, kidney stone pain, and musculoskeletal injuries, often given by injection in a clinic or emergency department and then sometimes continued as a short oral course. That profile overlaps heavily with the kind of workplace injury that triggers a post incident drug test, which is the real reason the question "does Toradol show up on a drug test" gets asked at all.
Why a standard panel does not target ketorolac
Workplace drug test cups and dip cards are built around immunoassay strips that are each designed to react to a specific drug class, such as amphetamines, opiates, cocaine metabolite, PCP, or THC metabolite. Those strips work because the antibody in the strip recognizes a chemical structure close to the target drug. Ketorolac is structurally an arylacetic acid NSAID, unrelated to opioid alkaloids, amphetamines, or any other class a standard 5 panel or 10 panel immunoassay is built to catch. It is simply not one of the analytes any panel configuration is designed to detect, so it does not read as a positive and it does not read as an opioid.
The federal workplace testing framework reflects the same structure. Under the regulations at 49 CFR 40.87, laboratories certified for federal drug testing programs screen specimens against a defined list of drugs and metabolites at set cutoff concentrations, and any initial positive has to be confirmed by a second, more specific method such as gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry before it can be reported as positive. NSAIDs including ketorolac are not on that target list, so there is no cutoff for a lab to apply and no confirmation test that would ever be run looking for it.
Is there any documented cross reactivity
Because ketorolac and other NSAIDs are so widely used after injuries, it is a fair question whether the drug class causes interference on an immunoassay strip. The ketorolac prescribing information on DailyMed documents the drug's real interaction risks in detail, including bleeding risk with anticoagulants, a contraindication against combining it with other NSAIDs or aspirin because of additive gastrointestinal and renal risk, and increased bleeding risk with SSRIs, but it does not list any laboratory test interference or urine drug screen cross reactivity. There is no credible published evidence of ketorolac producing a false positive on a standard opiate, amphetamine, PCP, benzodiazepine, or THC immunoassay. The honest answer is limited to no published cross reactivity, not a promise, and anyone with a specific lab result in question should raise it with the testing laboratory or the medical review officer rather than rely on a general article.
What happens with the medical review officer
Any positive result on a federally regulated test still has to clear a medical review officer, a licensed physician trained to review laboratory results before they are reported to an employer. Under 49 CFR 40.133, the MRO's job on a confirmed positive includes contacting the donor directly, giving them a chance to explain the result, and verifying any legitimate medical explanation such as a current prescription before a result is reported as positive to the employer. Separately, 49 CFR 40.129 describes what the MRO does once a laboratory reports a confirmed positive, adulterated, substituted, or invalid result, including requesting documentation from a prescribing provider when needed. Because ketorolac is not a target analyte in the first place, it will not generate a confirmed positive for the MRO to review, but any medication an injured employee is taking, including ketorolac, should still be documented at the time of the test so there is a record if a question comes up later. SAMHSA's drug testing resources page hosts the Medical Review Officer Manual and related guidance that federal program MROs are trained against, and the same verification principles are widely used by MROs reviewing non federal workplace programs as well.
Post injury medications compared to standard panel targets
| Medication | Drug class | Typically on a standard 5 or 10 panel screen | How a true positive would be resolved |
|---|---|---|---|
| Ketorolac (Toradol) | NSAID, non opioid analgesic | No, not a target analyte | Not applicable, no screen is built to detect it |
| Ibuprofen | NSAID | No, not a target analyte | Not applicable |
| Naproxen | NSAID | No, not a target analyte | Not applicable |
| Acetaminophen | Analgesic, non NSAID | No, not a target analyte | Not applicable |
| Hydrocodone | Semi synthetic opioid | Yes, opiate or expanded opioid panel | GC/MS or LC/MS confirmation, then MRO review of prescription |
| Oxycodone | Semi synthetic opioid | Yes, often requires an expanded opioid panel | GC/MS or LC/MS confirmation, then MRO review of prescription |
| Tramadol | Atypical, centrally acting opioid | Sometimes, depends on panel configuration | Confirmation testing, then MRO review |
| Morphine | Opioid | Yes, opiate panel | GC/MS or LC/MS confirmation, then MRO review of prescription |
What employers and employees should actually do
An employer running a post accident testing program should make sure the panel configuration matches the job and the drugs it is actually meant to detect, since an NSAID like ketorolac is never going to appear on a result regardless of panel size. Our related article on post accident drug testing and the OSHA rules employers get wrong walks through the recordkeeping and reasonable suspicion issues that come up around this kind of testing. If the concern is broader NSAID interference with a screen, our piece on whether naproxen causes a false positive drug test covers a different NSAID and a different panel question in more depth.
Employees who are prescribed or given ketorolac after an injury should tell the collector or the clinic about every medication they are taking at the time of a test, including over the counter NSAIDs, since that documentation is what protects them if any question comes up later. This is general information, not medical or legal advice, and it is not a substitute for a conversation with a treating provider or a medical review officer about a specific situation.
Employers building or restocking a post injury testing program can review cup, dip card, and oral fluid panel configurations, including options for expanded opioid panels, through the wholesale portal at wholesale.americanscreeningcorp.com, or browse individual panel configurations in the drug test cup collection.
Frequently asked questions
Does Toradol show up as an opioid on a drug test?
No. Toradol is ketorolac, an NSAID with a different chemical structure than opioid painkillers, and it is not a target analyte on standard opiate or expanded opioid immunoassay strips.
Is Toradol a controlled substance?
No. The ketorolac prescribing information on DailyMed lists its DEA schedule as none, meaning it is not scheduled as a controlled substance under federal law.
Can ketorolac cause a false positive on a standard drug test panel?
There is no credible published evidence of ketorolac producing a false positive on standard opiate, amphetamine, PCP, benzodiazepine, or THC immunoassay panels. The honest description is limited to no published cross reactivity rather than a promise for every panel brand or lot.
Who reviews a positive result if a medication might explain it?
A medical review officer, a licensed physician trained under 49 CFR Part 40, reviews confirmed positive results, contacts the person tested, and verifies any legitimate medical explanation such as a current prescription before a result is reported to an employer.
Should an injured worker tell the clinic they were given Toradol before a post accident test?
Yes. Documenting every medication given at the time of an injury, including ketorolac, protects the employee and gives the medical review officer accurate information if any question comes up, even though ketorolac itself is not a panel target.
Does lab confirmation testing change the answer for NSAIDs like ketorolac?
No. Confirmation methods such as GC/MS or LC/MS are run on specimens that already screened positive for a targeted drug class under 49 CFR 40.87. Since ketorolac is not a targeted analyte, it does not generate a screen result for a lab to confirm either way.
This article is general information about drug test panel design and federal review procedures, not medical or legal advice. Decisions about a specific test result should involve a medical review officer, a treating provider, or qualified counsel.
